Lack of Tocopherol in Peripheral Nerves of Vitamin E-Deficient Patients with Peripheral Neuropathy
NEJM 317:262-265, Traber,M.G.,et al, 1987
Update on Parkinson Disease
NY State J Med, 87:147-1531987., Lieberman,A.N., 1987
The Spectrium of Neurologic Disorder From Vitamin E Deficiency
Neurol 36:917-921, Satya-Murti,S.,et al, 1986
Electrophysiologic Features of Abetalipoproteinemia:Functional Consequences of Vitamin E Deficiency
Neurol 36:669-673, Brin,M.F.,et al, 1986
Improved Neurologic Function After Long-Term Correction of Vitamin E Deficiency in Children with Chronic Cholestasis
NEJM 313:1580-1586, Sokol,R.J.,et al, 1985
Vitamin E Deficiency Associated with Vision Loss & Bulbar Weakness
Ann Neurol 18:725-727, Larsen,P.D.,et al, 1985
Protective Effect of Vitamin E (DL-Alpha-Tocopherol) Against Intraventricular Haemorrhage in Premature Babies
BMJ 287:81-84, Chiswick,M.L.,et al, 1983
Vitamin E & Neurological Function
Lancet 1:225-228, Muller,D.P.R.,et al, 1983
Spinocerebellar Degeneration Secondary to Chronic Intestinal Malabsorption:A Vitamin E Deficiency Syndrome
Ann Neurol 12:419-424, Harding,A.E.,et al, 1982
Association Of Spinocerebellar Disorders With Cystic Fibrosis Or Chronic Childhood Cholestasis & Very Low Serum Vit. E
Lancet 2:1319-1321, Elias,E.,et al, 1981
Vitamin E Deficiency in Werdnig-Hoffmann Disease
Ann Neurol 10:266-268, Shapira,Y.,et al, 1981
Abetalipoproteinemia, Report of Two Cases & Review of Therapy
Arch Neurol 37:659-662, Illingworth,D.R.,et al, 1980
Proximal Myopathy after Prolonged Total Therapeutic Starvation
BMJ 280:1212-1213, Scobie,I.N.,et al, 1980
Reversibility of Human Myopathy Caused by Vitamin E Deficiency
Neurol 29:1182-1186, Tomasi,L.G., 1979
Degeneration of Fasciculus Gracilis in Cystic Fibrosis
Neurol 27:185, Geller,A.,et al, 1977
Diffuse"Anoxic"Myelopathy
Neurol 27:1049, Azzarelli,B.,et al, 1977
Post-Herpes Zoster Neuralgia:Response to Vitamin E Therapy
Arch Dermatol 108:855, Ayres,S.Jr.,et al, 1973
Familial Amyotrophic Lateral Sclerosis
Muscle Nerve 25:135-159, Hand,C.K. &Rouleau,G.A., 2002
Oxidative Damage in Neurodegenerative Disease
Lancet 344:796-798, Jenner,P., 1994
Superoxide Dismutase and ALS
Lancet 344:1651-1652, Orrell,R.W.&deBelleroche,J.S., 1994
The Free Radical Hypothesis in Idiopathic Parkinsonism:Evidence Against It
Ann Neurol 32:799-803, Calne,D.B., 1992
The Oxident Stress Hypothesis in parkinson's Disease:Evidence Supporting it
Ann Neurol 32:804-812, Fahn,S.&Cohen,G., 1992
Mitochondrial Oxidative Phosphorylation Defects in Parkinson's Disease
Ann Neurol 30:332-339, 3301991., Shoffner,J.M.,et al, 1991
Background Review and Current Concepts of Reperfusion Injury
Arch Neurol 47:1245-1254, Hallenbeck,J.M.&Dutka,A.J., 1990
Free Radicals in Central Nervous System Ischemia
Stroke 21:1086-1090, Schmidley,J.W., 1990
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025
Seizures, Driver Licensure, and Medical Reporting
Neurol 104:e213459, Tolchin,B.,et al, 2025
Inebilizumab for Treatment of IgG4-Related Disease
NEJM 392:1168-1177, Stone,J.H.,et al, 2025
Beyond Glucocorticoids for IgG4-Related Disease
NEJM 392:1232-1233, Spiera,R., 2025
Progress Toward Mitigating Disability Progression in Multiple Sclerosis
NEJM 392:1966-1968, Calabresi,P.A., 2025
Upadacitinib - An Up-and-Comer for Treatment of Giant-Cell Arteritis
NEJM 392:2062-2064, Koster,M.J. & Warrington,K.J., 2025
Inhibition of CD40L with Frexalimab in Multiple Sclerosis
NEJM 390:589-600, 662, Vermersch,P.,et al, 2024
Diagnosis and Management of ANCA-Associated Vasculitis
Lancet 403:683-698, Kronbichler, A., et al, 2024
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients with Atrial Cardiopathy, The ARCADIA Randomized Clinical Trial
JAMA 331:573-581, Kamel,H.,et al, 2024
Repurposing Erectile Dysfunction Medication for Alzheimer Disease Prevention
Neurol 102:e209180, Yasara,S., & Nidadavolu,L., 2024
Diagnosis and Management of Cerebral Venous Thrombosis:A Scientific Statement From the American Heart Association
Stroke 55:e77-e90, Saposnik,G.,et al, 2024
Optimal Timing of Anticoagulation after Acute Ischaemic Stroke with Atrial Fibrillation (OPTIMAS): A Multicentre, Blinded-Endpoint, Phase 4, Randomised Controlled Trial
Lancet 404:1731-1741, Werring,D.J.,et al, 2024
Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine, A Phase 4, Randomized, Placebo-Controlled Trial
JAMA Neurol 81:1140-1149, Tepper,S.J.,et al, 2024
Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage
NEJM 390:1745-1755, 1815, Connolly,S.J.,et al, 2024
Mechanical Thrombectomy in Anticoagulated Patients with Acute Ischemic Stroke, A Meta-Analysis
Neurologist 29:194-203, Zhang,H.L.,et al, 2024
Vitamin B12 Deficiency:NICE Guideline Summary
BMJ 385:q1019, q1262, Sands,T.,et al, 2024
Advances in Cerebral Venous Thrombosis
Stroke 55:2169-2172, deSousa,D.A. & Neto,L.L., 2024
Clinical Presentation, Management, and Outcome in Neurolymphomatosis, A Systematic Review
Neurol 103:e209698, Kaulen.L.D.,et al, 2024
Risk of Dementia After Initiation of Sodium-Glucose Cotransporter-2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors in Adults Aged 40-69 years with type 2 Diabetes:Population Based Cohort Study
BMJ doi:10.1136/BMJ-2024-07945, Shin,A., et al, 2024
Apixaban vs Aspirin in Patients with Cancer and Cryptogenic Stroke A Post Hoc Analysis of the ARCADIA Randomized Clinical Trial
JAMA Neurol 81:957-965, Navi,B.B.,et al, 2024
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Neurol 103:e209805, Kim,H.K.,et al, 2024
Thrombolysis After Dabigatran Reversal for Acute Ischemic Stroke
Neurol 103:e209862, Theodorou,A.,et al, 2024
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023